Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICRAININ vs TREZIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
Capsaicin is a TRPV1 receptor agonist that initially causes pain and neuropeptide release, followed by desensitization and depletion of substance P from sensory nerve terminals, reducing pain transmission. Hydrocodone is a mu-opioid receptor agonist, modulating pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, reducing prostaglandin synthesis and pain signaling.
Tension headache,Migraine (off-label),Muscle contraction headache
FDA-approved: Management of moderate to moderately severe pain where treatment with an opioid is appropriate,Off-label: Chronic pain syndromes, neuropathic pain
2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.
TREZIX (acetaminophen 320 mg, dichloralphenazone 100 mg, isometheptene mucate 65 mg) capsules: 2 capsules orally at onset of headache, then 1 capsule every hour until relief (maximum 5 capsules in 12 hours, 10 capsules in 24 hours). For migraine: 2 capsules orally at onset, then 1 capsule every hour as needed (maximum 5 capsules per attack).
Terminal elimination half-life 8-12 hours; in elderly or severe renal impairment, may extend to 24 hours
Terminal elimination half-life is approximately 2.5-3.5 hours for the parent compound; clinically, this necessitates dosing every 4-6 hours for sustained effect during wakefulness, but accumulation is minimal with normal hepatic and renal function.
Acetaminophen is primarily metabolized in the liver via glucuronidation and sulfation; a minor pathway via CYP2E1 and CYP3A4 produces the toxic metabolite NAPQI. Butalbital is extensively metabolized by CYP2C19 and other hepatic enzymes.
Hydrocodone: Hepatic metabolism via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone, respectively. Acetaminophen: Conjugation primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1), with minor CYP2E1 oxidation to NAPQI.
Primarily renal (70% unchanged, 20% as sulfate conjugate); biliary/fecal <10%
Renal excretion of metabolites (primarily as glucuronide conjugates and unchanged drug) accounts for approximately 55-65% of the dose; biliary/fecal elimination accounts for approximately 25-35%.
70-80% bound to albumin
Approximately 35-40% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg; indicates moderate distribution into total body water
Volume of distribution is approximately 3-4 L/kg, indicating extensive tissue distribution with penetration into the central nervous system.
Oral: 60-70% (due to first-pass metabolism); Intramuscular: 75-85%; Intravenous: 100%
Oral bioavailability is approximately 50-70% due to first-pass hepatic metabolism.
Not studied; use caution with Cr Cl <30 m L/min. Avoid if severe renal impairment (Cr Cl <15 m L/min) due to acetaminophen and dichloralphenazone accumulation. No specific dose adjustment guidelines available.
No specific GFR-based dose adjustments available; contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to acetaminophen and dichloralphenazone accumulation. Use with caution in moderate impairment (Cr Cl 30-60 m L/min); consider extending dosing interval to every 6-8 hours.
Contraindicated in severe hepatic impairment (Child-Pugh C). In moderate impairment (Child-Pugh B), reduce dose by 50% or increase dosing interval. In mild impairment (Child-Pugh A), no adjustment necessary but monitor.
Contraindicated in Child-Pugh class C (severe hepatic impairment). In Child-Pugh class A or B: reduce dose by 50% and monitor liver function; maximum acetaminophen daily dose should not exceed 2000 mg. Avoid in active liver disease.
Not recommended for pediatric patients due to lack of safety and efficacy data; alternative agents preferred.
Not recommended for children under 12 years due to lack of safety data. For adolescents 12-17 years: 1-2 capsules orally at onset, then 1 capsule every hour as needed (maximum 3 capsules in 12 hours). Weight-based dosing not established.
Use with caution due to increased sensitivity to anticholinergic effects, sedation, and hepatotoxicity. Initiate at lower doses (e.g., 1 tablet at onset) and titrate slowly. Monitor renal and hepatic function.
Initiate with lower dose (1 capsule at onset) and monitor closely due to increased sensitivity to anticholinergic effects of dichloralphenazone. Maximum daily acetaminophen dose not to exceed 3000 mg. May require longer dosing intervals (every 6-8 hours).
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; HEPATOTOXICITY (due to acetaminophen); RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Hepatotoxicity: Severe liver injury may occur with acetaminophen, especially with chronic use or doses >4000 mg/day. Monitor liver function. Dependence: Butalbital can cause tolerance and dependence; withdrawal symptoms may occur upon abrupt discontinuation. CNS depression: May impair mental and physical abilities; caution with alcohol or other CNS depressants. Renal impairment: Use with caution in patients with severe renal disease.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks with CYP3A4 inhibitors or discontinuation; hepatotoxicity from acetaminophen overdose; hypersensitivity reactions; severe hypotension; gastrointestinal obstruction; seizures; serotonin syndrome with concomitant serotonergic drugs; impaired mental/physical abilities; adrenal insufficiency; androgen deficiency.
Hypersensitivity to acetaminophen, butalbital, or any component; porphyria; severe hepatic impairment; history of barbiturate dependence.
Hypersensitivity to any ingredient; significant respiratory depression; acute or severe bronchial asthma in unmonitored settings; known or suspected gastrointestinal obstruction; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (due to acetaminophen).
Avoid excessive caffeine intake from coffee, tea, soda, or chocolate as it may increase caffeine-related side effects. Grapefruit juice may potentiate effects; limit consumption. Alcohol increases risk of drowsiness and hepatotoxicity.
Avoid alcohol. Limit caffeine from other sources (coffee, tea, soda) to prevent excessive stimulation. High-fat meals may delay absorption but do not significantly alter overall effect.
MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, particularly neural tube defects, when used in the first trimester. Chronic use in the third trimester can lead to neonatal withdrawal syndrome and floppy infant syndrome. Acetaminophen is generally considered low risk at therapeutic doses. Caffeine in moderate amounts is not strongly associated with major malformations, but high doses may increase risk of miscarriage.
TREZIX (acetaminophen, dichloralphenazone, isometheptene) is contraindicated in pregnancy. First trimester: risk of neural tube defects and other malformations due to acetaminophen? limited data but dichloralphenazone is a barbiturate derivative with known teratogenicity (cleft palate, cardiac defects). Second and third trimesters: barbiturates may cause neonatal dependence, withdrawal, and bleeding disorders (vitamin K deficiency). Late third trimester: maternal use of barbiturates may lead to neonatal respiratory depression and withdrawal. Avoid in all trimesters.
Butalbital is excreted into breast milk; the milk-to-plasma ratio is approximately 0.3-0.6. Infants are at risk of sedation, poor feeding, and withdrawal. Acetaminophen is excreted in low amounts (M/P ~0.2-0.9) and is considered compatible. Caffeine is excreted in breast milk (M/P ~0.5) and may cause irritability in infants. Use of MICRAININ during breastfeeding is generally not recommended due to butalbital.
No specific studies for TREZIX. Acetaminophen is compatible with breastfeeding (M/P ratio ~1.0). Dichloralphenazone (metabolized to trichloroethanol) and isometheptene: data lacking. Barbiturate metabolites may cause infant sedation, poor feeding, and withdrawal risk. Manufacturer advises caution; use alternative if possible.
No specific pharmacokinetic data for MICRAININ during pregnancy. Pregnancy can alter metabolism of acetaminophen and caffeine. Butalbital clearance may increase due to enhanced hepatic metabolism. However, dose adjustments are not typically recommended. Use the lowest effective dose for the shortest duration.
Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism, renal clearance) may reduce drug levels. However, TREZIX is contraindicated due to teratogenicity and maternal/fetal risks; therefore, no dosing adjustment is recommended. Alternative therapy should be used.
MICRAININ is a fixed-dose combination of butalbital, acetaminophen, and caffeine, used for tension-type headache. Butalbital is a barbiturate with abuse potential; limit quantity prescribed. Acetaminophen hepatotoxicity risk with >3000 mg/day. Caffeine may exacerbate anxiety or insomnia. Avoid in porphyria, severe hepatic impairment, or history of substance abuse. Contraindicated with MAOIs.
TREZIX (acetaminophen, caffeine, and dihydrocodeine) is a fixed-dose combination analgesic with abuse potential; monitor for opioid-induced constipation and respiratory depression. Avoid exceeding 4 grams/day of acetaminophen due to hepatotoxicity risk. Caffeine may potentiate analgesic effects but can cause insomnia and anxiety. Discontinue prior to surgery to avoid withdrawal and respiratory complications.
Take exactly as prescribed; do not increase dose or frequency.,Avoid alcohol while taking this medication.,Do not exceed 4000 mg acetaminophen per day from all sources.,This medication can be habit-forming; do not share with others.,May cause drowsiness; avoid driving or operating machinery until you know how it affects you.,Report signs of liver injury: yellowing skin/eyes, dark urine, abdominal pain.,Do not use for more than 5 days per week to avoid rebound headaches.
Take exactly as prescribed; do not increase dose or frequency without doctor approval.,Do not combine with other acetaminophen-containing products to avoid liver damage.,Avoid alcohol while taking this medication.,Do not drive or operate heavy machinery until you know how TREZIX affects you.,Report severe constipation, difficulty breathing, or signs of allergic reaction immediately.,Do not stop suddenly; taper under medical supervision to prevent withdrawal.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICRAININ vs TREZIX, answered by our medical review team.
MICRAININ is a Barbiturate Combination Analgesic that works by MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.. TREZIX is a Barbiturate Combination Analgesic that works by Capsaicin is a TRPV1 receptor agonist that initially causes pain and neuropeptide release, followed by desensitization and depletion of substance P from sensory nerve terminals, reducing pain transmission. Hydrocodone is a mu-opioid receptor agonist, modulating pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, reducing prostaglandin synthesis and pain signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICRAININ and TREZIX depend on the specific clinical indication. These are both Barbiturate Combination Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICRAININ is: 2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.. The standard adult dose of TREZIX is: TREZIX (acetaminophen 320 mg, dichloralphenazone 100 mg, isometheptene mucate 65 mg) capsules: 2 capsules orally at onset of headache, then 1 capsule every hour until relief (maximum 5 capsules in 12 hours, 10 capsules in 24 hours). For migraine: 2 capsules orally at onset, then 1 capsule every hour as needed (maximum 5 capsules per attack).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICRAININ and TREZIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICRAININ is classified as Category C. MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, par. TREZIX is classified as Category C. TREZIX (acetaminophen, dichloralphenazone, isometheptene) is contraindicated in pregnancy. First trimester: risk of neural tube defects and other malformations due to acetaminophen. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.